The new results with a once-weekly subcutaneous injection of amycretin ... The results are a boost to Novo Nordisk after another weight-loss therapy, CagriSema (cagrilintide and semaglutide ...

There are obesity therapies ahead of the queue in Novo Nordisk’s pipeline, including an oral formulation of semaglutide, due to report phase 3 results later this year, as well as CagriSema ...

Says Novo Nordisk's Martin Holst Lange, executive VP and head of clinical development: We expect the first phase 3 results from CagriSema [in type 2 diabetes], as well as phase 2 results for both ...

Novo Nordisk's phase 3 CagriSema study on obesity, named "REDEFINE-1." Defendants' statements failed to disclose or otherwise misled investors as to the nature of the dosages provided to patients ...

NEW YORK, NY / ACCESS Newswire / February 14, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE ... safety trial investigating subcutaneous CagriSema." The trial showed that patients ...

Pharmaceutical giant Novo Nordisk (NYSE: NVO) released its fourth-quarter and full-year earnings report on Feb. 5. The Denmark-based company performed pretty well, leading to a post-earnings jump ...

Europe's STOXX 600 closes higher on healthcare boost; auto stocks slide February 5, 2025 Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late ...

In the GLP-1 weight loss market, it's largely been a two-horse race between Eli Lilly and Novo Nordisk (NYSE: NVO). The two companies have approved weight loss drugs that are generating billions ...